Abbott Laboratories (Pakistan) Limited manufactures, imports, and markets generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products in Pakistan, Afghanistan, Sri Lanka, Bangladesh, and Switzerland. It operates through Pharmaceutical, Nutritional, Diagnostics, and Others segments. The company engages in the manufacturing, importing, and marketing of branded generic pharmaceutical products; and import and marketing of nutritional products. It also imports and markets diagnostic equipment, m... [
ABOT — Abbott Laboratories (Pakistan) Limited
Sector: Pharmaceuticals · Pakistan Stock Exchange
⚠ Prices: 6 Nov 2026 — PSX end-of-day close (feed fetched 23:14 PKT) · Fundamentals: public data collected 6 Nov 2026 · Not live prices.Summary — ABOT
| Measure | Value |
|---|---|
| Price (Rs, 6 Nov — PSX delayed feed) | 989.89 |
| Change, 6 Nov session (delayed) | -1.04% |
| Volume (shares, 6 Nov session) | 4,509 |
| Market capitalisation | Rs 96.91 bn |
| Revenue (TTM) | Rs 77.83 bn |
| Price / Earnings (P/E) | 11.00 |
| Price / Book (P/B) | 2.93 |
| Dividend yield | 4.20% |
| Return on equity (ROE) | 28.80% |
| Net margin | 10.60% |
| Debt / Equity (as reported by source) | 1.50% |
| Revenue growth, 3-year | 15.20% |
Company Snapshot
| Paid-up Capital | Rs 979.00 mn |
| Authorized Capital | Rs 2,000.00 mn |
| Shares Outstanding | 97.90 mn |
| Free Float | 21.17 mn |
| Free Float % | 21.63 % |
| Face Value | Rs 10.00 |
| Fiscal Year End | December |
| Avg Volume (12M) | 27,415 |
| Book Value / Share | Rs. 355.11 (Upto 2026 3Q) |
| Total Book Value (computed) | Rs 34.77 bn |
Capital data: SCSTRADE company snapshot, collected 6 Nov 2026. Total Book Value is computed on this page as Book Value / Share × Shares Outstanding.
PSX Scorecard — five checks on this stock's own data
VALUE
6/6
FUTURENo forecast data
PAST
5.5/6
HEALTH
6/6
DIVIDEND
4.5/6
Strongest: Value (6/6). Weakest: Dividend (4.5/6).
How this is scored
Scores are computed mechanically from the data on this page, 0–6 per axis, scaled over the checks that could be run — an axis with no data is labelled, never scored zero for missing data. VALUE: upside to the average analyst target (bands from +30% down), P/E and P/B below the sector median, yield above the sector median. FUTURE: S&P consensus forward EPS and revenue growth bands (only where estimates exist). PAST: revenue and EPS growth across the published financial history, latest year profitable, ROE bands. HEALTH: debt/equity bands, positive latest net margin, no loss-making year in the history. DIVIDEND: yield bands, years of recorded DPS, DPS trend, and payout (DPS ÷ EPS) at or under 100%. The full rule table is in the site's data inventory. Scores are a data summary, not a recommendation.
Performance — ABOT
1W+2.9%
1M+10.3%
3M+8.0%
6M+11.5%
1Y-9.0%
Returns computed from daily closes to 05 Nov 2026 (Yahoo Finance PSX series, collected 6 Nov 2026); each bar is scaled to the largest move shown.
52-week range — daily-close series
52-week lowRs 836.92Now Rs 989.89
+18.3% above low · −21.3% below high52-week highRs 1,257.76
+18.3% above low · −21.3% below high52-week highRs 1,257.76
Day range — 6 Nov 2026 session
Day lowRs 957.00Close Rs 989.89Day highRs 1,025.60
Day high/low from the official PSX market-summary feed for the 6 Nov 2026 session.
Investment Case — ABOT
Strengths — from the numbers
- Revenue grew +77.1% across the published history, FY2021–FY2025 (Rs 42,570m → Rs 75,398m).
- Earnings per share grew +33.5% across the published history, FY2021–FY2025 (Rs 60.95 → Rs 81.37).
- Return on equity of 28.80% on the dataset's trailing figures.
- Debt/equity of 0.01 — below 1 (the source reports this figure as 1.50%).
- Dividends recorded in every one of the 4 years in the published record; latest DPS Rs 40.00 (2025), a dividend yield of 4.20% at the current price.
Risks / watch points — from the numbers
- Net margin has fallen to 10.57% in FY2025, from 14.02% in FY2021.
- No dividend was recorded for 2023 in the source's dividend history.
- Share price is down -9.0% over the past year on the chart series (2025-11-06 → 2026-11-05).
Recent performance — FY2025
| Revenue | Rs 75,398m (+10.6% vs FY2024) |
| Net income | Rs 7,967m (+52.2% vs FY2024) |
| EPS | Rs 81.37 (+52.2% vs FY2024) |
| Net margin | 10.57% |
Latest published fiscal year from the financial history below (StockAnalysis figures, collected 6 Nov 2026).
Generated from the figures above — PSX Analysis data summary, not investment advice.
Upcoming Result — Broker Forecasts
Expected Dividend — Broker Estimate
| House | Expected dividend / share | Expected yield |
|---|---|---|
| SCSTRADE (Standard Capital Securities) | Rs 44.75 | 4.52% |
House's published expected dividend, Upto 2026 3Q — SCSTRADE company snapshot, collected 7 Nov 2026.
Forecasts are the publishing houses' own estimates — not actual results and not PSX Analysis estimates.
Quotes — ABOT
| Quote | Value |
|---|---|
| Last price (Rs) | 989.89 |
| Change, 6 Nov session | -1.04% |
| Day open, 6 Nov (Rs) | 1,025.60 |
| Day high, 6 Nov (Rs) | 1,025.60 |
| Day low, 6 Nov (Rs) | 957.00 |
| Previous close — LDCP (Rs) | 1,000.30 |
| Volume (shares, 6 Nov session) | 4,509 |
| Market capitalisation | Rs 96.91 bn |
| 1-year high (chart series, Rs) | 1,257.76 |
| 1-year low (chart series, Rs) | 836.92 |
| 1-year change (chart series) | -9.0% |
Day open/high/low and previous close (LDCP) are from the official PSX market-summary feed for the 6 Nov 2026 session, the same feed that supplies the closing price. 1-year figures are computed from the daily-close chart series below.
Last 10 trading sessions
| Date | Close (Rs) | Change |
|---|---|---|
| 05 Nov 2026 | 1,000.30 | +3.18% |
| 04 Nov 2026 | 969.50 | +0.98% |
| 03 Nov 2026 | 960.06 | +0.17% |
| 02 Nov 2026 | 958.42 | -0.86% |
| 30 Oct 2026 | 966.69 | -0.52% |
| 29 Oct 2026 | 971.75 | +1.15% |
| 28 Oct 2026 | 960.74 | -0.66% |
| 27 Oct 2026 | 967.16 | +4.65% |
| 26 Oct 2026 | 924.15 | -0.38% |
| 23 Oct 2026 | 927.67 | +0.03% |
Daily closes: Yahoo Finance PSX series, collected 6 Nov 2026. The series records closes only, so no volume column is shown.
Technical Chart — ABOT
Loading chart…
Daily candles — Yahoo Finance daily data to 6 Nov 2026 · End-of-day, delayed — not real-time prices.
2024-11-06 → 2026-11-06 · +9.0% over the period · 514 trading days · Moving averages, RSI and MACD are computed in your browser from the same daily bars. Trend lines connect the two most recent swing highs/lows.
1-year returns compared
| 1-year price change | Change |
|---|---|
| ABOT (this stock) | -9.0% |
| Sector median — Pharmaceuticals (median of 12 stocks in our dataset) | -13.0% |
| All listed stocks median (median of 440 stocks in our dataset) | -6.2% |
Price change only (dividends not included), from the daily-close series above.
Technicals — ABOT
Moving averages
| Average | Value (Rs) | Price vs average |
|---|---|---|
| MA20 — 20-session average | 947.69 | Price Above |
| MA50 — 50-session average | 933.52 | Price Above |
| MA200 — 200-session average | 949.69 | Price Above |
RSI (14) — 71.9 · Overbought
030 — oversold below70 — overbought above100
Wilder RSI(14) computed from the daily-close series. RSI is a momentum gauge, not a buy or sell signal.
Classic pivot levels — from the 6 Nov session
| Level | Rs |
|---|---|
| Resistance 2 (R2) | 1,059.43 |
| Resistance 1 (R1) | 1,024.66 |
| Pivot point (PP) | 990.83 |
| Support 1 (S1) | 956.06 |
| Support 2 (S2) | 922.23 |
Classic pivots from the 6 Nov 2026 session's high (Rs 1,025.60), low (Rs 957.00) and close (Rs 989.89) in the official PSX feed. The close sits below the pivot point.
Signals summary
| Reading | Status |
|---|---|
| Price vs MA20 | Above |
| Price vs MA50 | Above |
| Price vs MA200 | Above |
| RSI (14) zone | Overbought (71.9) |
| MACD vs signal line | Above |
| Short-term trend (MA20 vs MA50) | Up |
| Medium-term trend (MA50 vs MA200) | Down |
| Long-term trend (price vs MA200) | Up |
Trend labels compare the named averages (long-term compares the price with MA200); “Up” means the first-named sits above the second. Mechanical readings from daily closes — not investment advice.
Technicals are mechanical calculations on past prices. Based on daily closes to 05 Nov 2026. They describe momentum and recent trading ranges only — not investment advice.
Company — ABOT
| Company | Abbott Laboratories (Pakistan) Limited |
| Symbol | ABOT |
| Sector | Pharmaceuticals |
| Market capitalisation | Rs 96.91 bn |
| Revenue (TTM) | Rs 77.83 bn |
Founded 1888 · Employees 1,380 — as published by StockAnalysis.
Company description: StockAnalysis company profile, collected 6 Nov 2026.
Exchange record: PSX company profile for ABOT (Pakistan Stock Exchange data portal).
Financials — ABOT
Revenue (TTM)
Rs 77,827m
Rs 77,827m
Net income (TTM)
Rs 9,285m
Rs 9,285m
EPS (TTM)
Rs 94.84
Rs 94.84
Net margin (TTM)
11.93%
11.93%
P/E
11.00
11.00
P/B
2.93
2.93
Dividend yield
4.20%
4.20%
ROE
28.80%
28.80%
Net margin
10.60%
10.60%
Debt / Equity
1.50%
1.50%
| Measure | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue (Rs m) | 42,570 | 49,258 | 55,475 | 68,177 | 75,398 |
| Operating income (Rs m) | 8,006 | 6,011 | 2,468 | 8,669 | 12,947 |
| Net income (Rs m) | 5,967 | 3,004 | 262 | 5,234 | 7,967 |
| EPS (Rs) | 60.95 | 30.69 | 2.67 | 53.46 | 81.37 |
| Net margin | 14.02% | 6.10% | 0.47% | 7.68% | 10.57% |
Trailing twelve months (to Sep 30, 2026, not a completed fiscal year): Revenue Rs 77,827m · Net income Rs 9,285m · EPS Rs 94.84 · Net margin 11.93%.
Source: StockAnalysis financials, collected 6 Nov 2026 — this stock's published history here spans FY2021–FY2025 (5 fiscal years; the source table publishes a maximum of five completed years per stock). A dash means the source did not publish that figure for that year.
Dividend History
| Dividend per share (Rs, per fiscal year) | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| DPS | 40 | 15 | 10 | 40 |
A dash means no dividend was recorded for that year in the source. Source: StockAnalysis dividend history, collected 6 Nov 2026.
All recorded dividend payments
Payments recorded since 2021 — StockAnalysis, collected 7 Nov 2026.
| Ex-dividend date | Dividend (Rs) | Pay date |
|---|---|---|
| Apr 22, 2026 | 40.000 | May 11, 2026 |
| Apr 14, 2025 | 10.000 | Apr 29, 2025 |
| Sep 8, 2022 | 15.000 | Sep 23, 2022 |
| Apr 15, 2022 | 20.000 | May 9, 2022 |
| Sep 8, 2021 | 20.000 | Sep 22, 2021 |
Payout ratio, FY2025: dividend per share Rs 40.00 ÷ EPS Rs 81.37 = 49.2% of earnings paid out as dividends.
Valuation & Fair Value — ABOT
Fair P/E Value — sector multiple
Rs 1,166.53
Current price Rs 989.89 · +17.8%
Formula: sector median P/E 12.30× × EPS Rs 94.84 = Rs 1,166.53. Sector median across 12 Pharmaceuticals peers with a published P/E — the same basis as the median table below. EPS is the trailing-twelve-month (TTM) figure published in the dataset.
Fair P/B Value — sector multiple
Rs 1,044.02
Current price Rs 989.89 · +5.5%
Formula: sector median P/B 2.94× × book value per share Rs 355.11 = Rs 1,044.02. Sector median across 11 Pharmaceuticals peers with a published P/B — the same basis as the median table below. Book value per share from the SCSTRADE company snapshot (Upto 2026 3Q), collected 6 Nov 2026.
2 of 2 measures above the current price. Each measure stands on its own stated basis — they are deliberately not blended into a single fair value. Mechanical estimates computed from published data; not investment advice.
| Measure | ABOT | Sector median |
|---|---|---|
| Price / Earnings (P/E) | 11.00 | 12.30 |
| Price / Book (P/B) | 2.93 | 2.94 |
| Dividend yield | 4.20% | 1.50% |
| Return on equity (ROE) | 28.80% | 21.65% |
Sector median across 14 listed peers in our dataset (sector: Pharmaceuticals), computed only from peers where the measure is published; a median is shown only when at least 5 peers have the measure.
Calendar — ABOT
| Ex-dividend date | Dividend (Rs) | Pay date | Status |
|---|---|---|---|
| Apr 22, 2026 | 40.000 | May 11, 2026 | Paid |
| Apr 14, 2025 | 10.000 | Apr 29, 2025 | Paid |
| Sep 8, 2022 | 15.000 | Sep 23, 2022 | Paid |
| Apr 15, 2022 | 20.000 | May 9, 2022 | Paid |
| Sep 8, 2021 | 20.000 | Sep 22, 2021 | Paid |
Dividend dates as recorded by StockAnalysis (collected 6 Nov 2026); past payments are labelled Paid. Market-closed days that affect settlement: PSX Holidays 2026 · more yields and payers on the dividend hub.
Sector — ABOT
ABOT ranks #2 by market capitalisation among the 14 listed Pharmaceuticals stocks in our dataset. Full sector tables: Sectors.
FAQ — ABOT
What is the current ABOT share price?
Abbott Laboratories (Pakistan) Limited (ABOT) last traded at Rs 989.89 in the 6 Nov 2026 session, -1.04% on the day. Prices on this page are the PSX end-of-day close from the official delayed feed, not live prices.
What is ABOT's 52-week range?
Across the daily-close series (2025-11-06 to 2026-11-05), ABOT traded between Rs 836.92 and Rs 1,257.76. The latest close in the series was Rs 1,000.30.
Which PSX sector is ABOT in?
Abbott Laboratories (Pakistan) Limited (ABOT) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
What is the latest ABOT dividend?
Total dividend per share for fiscal 2025 was Rs 40.00; the most recent recorded payment is Rs 40.00 per share (ex-date Apr 22, 2026, pay date May 11, 2026). Dividend history as recorded by StockAnalysis, collected 6 Nov 2026.
What are ABOT's P/E ratio and dividend yield?
Abbott Laboratories (Pakistan) Limited (ABOT) shows a P/E ratio of 11.00 and a dividend yield of 4.20% in the public data collected 6 Nov 2026.
Answers are generated from this page's own figures (public data collected 6 Nov 2026; prices are the 6 Nov 2026 PSX end-of-day close, not live).
Abbott Laboratories (Pakistan) Limited (ABOT) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
Every figure above comes from public listings collected on 6 November 2026 (StockAnalysis and SmartMoney, merged by symbol), with the price, change and volume refreshed on 6 Nov 2026 from the official PSX delayed market feed (end-of-day close, fetched 23:14 PKT) — delayed figures, not live prices. If this stock was absent from that feed, its price is the previous latest close. A dash means the measure was not published for this stock by the sources, not that it is zero. Compare ABOT with the market's largest shares in the Top 250 screener, browse the whole market in Stocks A–Z, and read the ratios explainer in Learn.
This page is a data summary for education, not a recommendation to buy or sell ABOT.